Literature DB >> 25010685

Recent advances in pancreatic surgery.

Filip Bednar1, Diane M Simeone.   

Abstract

PURPOSE OF REVIEW: To appraise the recent literature dealing with important advances in the field of pancreatic surgery. RECENT
FINDINGS: Surgical care for pancreatic cancer patients remains fractured, with imperfect patient selection and ongoing bias in referral patterns based on socioeconomic factors. Analysis of readmissions after pancreatectomy reveals it to be a poor quality of care metric. More extensive pancreatic resections lead to higher morbidity. Intraductal papillary mucinous neoplasm and pancreatic neuroendocrine tumor biology affect patient outcomes and suggest the need for better diagnostic approaches for these entities. Perioperative drainage still has a role during Whipple pancreaticoduodenectomy on the basis of the results of a randomized controlled trial. Laparoscopic and robotic approaches married with new emerging technologies have the potential to transform the practice of pancreatic surgery.
SUMMARY: Pancreatic surgery is a rapidly evolving field with the promise to significantly improve outcomes for patients with a variety of pancreatic diseases in the future.

Entities:  

Mesh:

Year:  2014        PMID: 25010685     DOI: 10.1097/MOG.0000000000000096

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  9 in total

1.  Next generation sequencing and functional pathway analysis to understand the mechanism of action of copper-tolfenamic acid against pancreatic cancer cells.

Authors:  Myrna Hurtado; Laszlo Prokai; Umesh T Sankpal; Blair Levesque; Rajasekhar Maram; Jaya Chhabra; Deondra T Brown; Raj K Gurung; Alvin A Holder; Jamboor K Vishwanatha; Riyaz Basha
Journal:  Process Biochem       Date:  2019-10-30       Impact factor: 3.757

2.  Hyperthermia enhances the sensitivity of pancreatic cancer SW1990 cells to gemcitabine through ROS/JNK signaling.

Authors:  Hangbin Jin; Yanyan Zhao; Jianfeng Yang; Xiaofeng Zhang; Shenglin Ma
Journal:  Oncol Lett       Date:  2018-09-18       Impact factor: 2.967

3.  A novel DDR1 inhibitor enhances the anticancer activity of gemcitabine in pancreatic cancer.

Authors:  Soyeon Ko; Kyung Hee Jung; Young-Chan Yoon; Beom Seok Han; Min Seok Park; Yun Ji Lee; Sang Eun Kim; Ye Jin Cho; Pureunchowon Lee; Joo Han Lim; Ji-Kan Ryu; Kewon Kim; Tae Young Kim; Sungwoo Hong; So Ha Lee; Soon-Sun Hong
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

Review 4.  The role of artificial intelligence in pancreatic surgery: a systematic review.

Authors:  D Schlanger; F Graur; C Popa; E Moiș; N Al Hajjar
Journal:  Updates Surg       Date:  2022-03-02

5.  Pancreatic cancer stromal biology and therapy.

Authors:  Dacheng Xie; Keping Xie
Journal:  Genes Dis       Date:  2015-06-01

6.  miR-30d suppresses proliferation and invasiveness of pancreatic cancer by targeting the SOX4/PI3K-AKT axis and predicts poor outcome.

Authors:  Xiaodong Xu; Ke Zong; Xinxing Wang; Dongwei Dou; Pengwei Lv; Zhe Zhang; Hongwen Li
Journal:  Cell Death Dis       Date:  2021-04-06       Impact factor: 8.469

7.  Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment.

Authors:  Kunpeng Wang; Xiongying Miao; Fanhua Kong; Siqi Huang; Jinggang Mo; Chong Jin; Yanwen Zheng
Journal:  Drug Des Devel Ther       Date:  2021-09-04       Impact factor: 4.162

8.  Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer.

Authors:  Wanyuan Chen; Weimin Fan; Guoqing Ru; Fang Huang; Xiaming Lu; Xin Zhang; Xiaozhou Mou; Shibing Wang
Journal:  Oncol Rep       Date:  2018-10-24       Impact factor: 3.906

9.  Standardization of perioperative care facilitates safe discharge by postoperative day five after pancreaticoduodenectomy.

Authors:  Sara K Daniel; Lucas W Thornblade; Gary N Mann; James O Park; Venu G Pillarisetty
Journal:  PLoS One       Date:  2018-12-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.